ClinicalTrials.gg
Not yet recruitingNCT07940192NNS-OHUpdated Nov 16, 2026

Phenotype of Alcohol-Related Nutritional Sensory Neuronopathies and Comparison With Dysimmune and Paraneoplastic Forms

An observational study in Sensory Neuropathy, sponsored by Centre Hospitalier Universitaire de Saint Etienne. Not yet recruiting at 14 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Centre Hospitalier Universitaire de Saint Etienne · Observational

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
145
Ages
18 Years and older
Sex
All
01

Study summary

Sensory neuronopathies (SNNs) are rare disorders characterized by damage to sensory neurons in the dorsal root ganglia. They may have dysimmune, paraneoplastic, toxic, or genetic causes. Alcohol-related nutritional sensory neuronopathy has recently been described and may present acutely or subacutely with pain, mimicking dysimmune or paraneoplastic disease. Distinguishing these causes early may help guide appropriate management. This international, multicentre, retrospective observational cohort study will describe the initial and follow-up clinical and electrophysiological phenotype of acute/subacute alcohol-related nutritional SNN and compare it with dysimmune and paraneoplastic SNN. Data will be abstracted from existing medical records. The protocol anticipates approximately 75 participants with alcohol-related nutritional SNN, 50 with dysimmune SNN, and 20 with paraneoplastic SNN. No additional procedure is performed for research purposes and no direct benefit is expected for participants.

02

Conditions studied

  • Sensory Neuropathy

Keywords

  • sensory neuropathy
  • retrospective cohort
  • alcohol-related neuropathy
03

In context

Lead sponsor

Centre Hospitalier Universitaire de Saint Etienne is the lead sponsor of 598 studies on the registry; 128 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients monitored in a neurology department for their sensory neuropathies

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years.
  • Probable sensory neuronopathy according to the diagnostic criteria of Camdessanché et al.
  • Acute or subacute onset (0-6 months).
  • One of the following aetiologies: Alcohol-related nutritional SNN: chronic alcohol misuse (>100 g/week for at least 3 months) and/or biological markers of alcohol consumption, with dysimmune and paraneoplastic causes excluded. The minimum work-up includes an immune laboratory assessment including serum anti-neuronal antibodies, lumbar puncture, and thoraco-abdominal imaging. Dysimmune SNN: associated with Sjögren's syndrome, lupus, primary biliary cholangitis, anti-FGFR3 antibodies, or anti-AGO antibodies. Paraneoplastic SNN: associated with anti-Hu or anti-CV2/CRMP5 antibodies.

Exclusion criteria

Exclusion Criteria :

  • Exposure to platinum salts before the onset of sensory neuronopathy.
  • Known hereditary neuropathy.
  • Patient under guardianship or curatorship (tutelle or curatelle).
  • Patient objection to the use of their data for the study.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
145 participants (estimated)
Patient registry
No

Groups and cohorts

  • Alcohol-related nutritional sensory neuronopathy

    Adults with probable acute/subacute SNN attributed to chronic alcohol misuse (\>100 g ethanol/week for at least 3 months) and/or biological markers of alcohol consumption, with dysimmune and paraneoplastic causes excluded using the minimum work-up specified in the protocol.

  • Dysimmune sensory neuronopathy

    Adults with probable acute/subacute SNN attributed to Sjögren's syndrome, lupus, primary biliary cholangitis, or associated with anti-FGFR3 or anti-AGO antibodies.

  • Paraneoplastic sensory neuronopathy

    Adults with probable acute/subacute SNN associated with anti-Hu or anti-CV2/CRMP5 antibodies.

06

What researchers measure

Primary outcomes

  1. Demographic and disease onset characteristics

    Description of demographic characteristics and disease onset, including age at onset (years), mode of onset, and initial symptoms. Each variable will be reported individually, as available in the medical records.

    Time frame: from july 2006 to april 2027

07

Study locations

14 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Apr 2027, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2026
First posted
Nov 16, 2026
StartEst.
Nov 2, 2026
Primary completionEst.
Apr 30, 2027
CompletionEst.
Apr 30, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07940192
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Nov 2, 2026 (estimated)
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Jean-Philippe CAMDESSANCHE, PUPH
Contact
j.philippe.camdessanche@chuse.fr
04 77 12 78 05 ext. +33
Jean-Phillippe CAMDESSANCHE, PUPH
principal investigator · CHU de Saint-Etienne

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion